WHO vaccine-preventable diseases: monitoring system. 2015 global summary

Last updated 15-Jul-2015 (Data received as of 10-Jul-2015)
Next overall update Fall 2015
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 1 Infant (under 12 months) mortality rate: 122
GDP / capita (US$): 1 Child (under 5 years) mortality rate: 152

Population data in thousands3

  2014  2013  2012  2011  2010  2000  1990  1980 
Total population 21'987  21'898  21'890  21'804  21'533  16'371  12'452  8'956 
Births 533  532  529  526  523  496  445  400 
Surviving infants 524  522  520  518  514  486  432  380 
Pop. less than 5 years 2'560  2'588  2'624  2'644  2'640  2'399  2'137  1'753 
Pop. less than 15 years 7'651  7'684  7'738  7'752  7'695  6'681  5'842  4'363 
Female 15-49 years 5'595  5'582  5'594  5'590  5'538  4'062  2'710  1'847 

Number of reported case

(Click for retrospective incidence data for Syrian Arab Republic (the))
Diphtheria 80  366 
Japanese encephalitis
Measles 594  740  13  13  26  146  535  1'478 
Mumps 45  52  95  145  7'780 
Pertussis 35  90  70  124  39  430 
Polio* 35  13  312 
Rubella 20 
Rubella (CRS)
Tetanus (neonatal) 15  55  91 
Tetanus (total)** 13  17  71  244 
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Syrian Arab Republic (the))
Vaccine year result method % card seen                                                
BCG 2008  93  PAPFAM   66  83  86  84  99*  99*  99*  92  35 
DTP1 2008  88  PAPFAM   66  76  66  79  97  99*  98  93 
DTP3 2008  82  PAPFAM   66  62  60  64  91  99  97  91  13 
DTP4          66 
IPV1          76 
HepB_BD          80  84  83  98  99*  99* 
HepB3 2005  77  MICS   55  62  86  58  81  99  90 
Hib3          62  60  64  91  99 
JapEnc         
MCV1          71  83  78  97  99  96  87  13 
MCV2          66  75  70  88  99  92 
PCV1         
PCV3         
Pol3 2008  81  PAPFAM   66  68  80  68  91  99  97  91  13 
Rota1         
Rota_last         
Rubella1          71  83  78  97 
TT2plus 1989  51  EPI   70  10  11  16  28  20  63 
PAB         
VAD1          71  64  78  59  90  94 
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: Mid July 2016

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Syrian Arab Republic (the))
BCG 81  84  82  90  97  91  92  35 
DTP1 65  55  68  86  89  90  93  35 
DTP3 43  41  45  72  80  84  91  13 
HepB3 71  71  43  66  84  79 
HepB_BD 78  81  81  89  97  91 
Hib3 43  41  45  72  80 
MCV1 54  58  61  80  82  84  87  13 
MCV2 49  51  53  71  82  80 
PAB 92  94  94  94  94  90  63 
PCV3
Pol3 52  52  52  75  83  86  91  13 
Rota_last

Number of districts in the country 81  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
93 
   
/
|
|
\
Greater or equal to 90% 16
From 80 to 89% 11
From 50 to 79% 73
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2014 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DTaPHibIPV 2, 4, 6, 18 months; Yes
DTwPHib 2, 4, 6, 18 months; Yes according the availablility of vaccines
DTwPHibHepB 2, 4, 6, 18 months; Yes according the availablility of vaccines
HepB birth; 2, 6 months; Yes
IPV 2, 4 months;
MMR 12, 18 months; Yes
Measles 9 months;
MenACWY 6 years; Yes
OPV 6, 12, 18 months; 6 years; Yes
TT 1st contact; +1, +6 months; +1, +1 year; Yes CBAW
Td 6, 12 years; Yes
VitaminA 12, 18 months; Yes

Immunizaton indicators

Indicator Expected answer 2014  2013  2012  2011  2010  2009  2008 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number   2013-2014  2011-2012  2006-2011  2006-2010  2006-2010  2006-2010 
Nº of districts with microplans that include activities to raise immunization coverage number 81  75  75  75  75  71  71 

System performance

Total Nº districts in country number 81  75  75  75  75  71  71 
Nº districts with DTP3 coverage >=80% number 22  15  75  71  71 
% of districts with DTP3 coverage >=80% From 0 to 100% 27  20  100  100  100 
Nº districts with measles (MCV1) coverage >=95% number     75    63 
% of districts with MCV1 coverage >=95% From 0 to 100%   100    89 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100%           100  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes     

Sources

 1  "The 2015 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.